Potential anti-epileptic phytoconstituents: An updated review

• Published in: Journal of ethnopharmacology Vol. 268; p. 113565
• Main Authors: Kaur, Jaskiran, Famta, Paras, Famta, Mani, Mehta, Meenu, Satija, Saurabh, Sharma, Neha, Vyas, Manish, Khatik, Gopal Lal, Chellappan, Dinesh Kumar, Dua, Kamal, Khurana, Navneet
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 25.03.2021
• Subjects: Animals; Anticonvulsants - isolation & purification; Anticonvulsants - therapeutic use; Epilepsy; Epilepsy - diagnosis; Epilepsy - drug therapy; Epilepsy - metabolism; Ethnopharmacology - methods; Humans; Medicinal plants; Medicine, Traditional - methods; Pharmacological activity; Phytochemicals - isolation & purification; Phytochemicals - therapeutic use; Phytoconstituents; Plant Extracts - isolation & purification; Plant Extracts - therapeutic use; Plants, Medicinal; Traditional uses; Medicinal plants; Traditional uses; Pharmacological activity; Epilepsy; Phytoconstituents
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2020.113565

Epilepsy is one of the most commonly occurring non-communicable neurological disorder that affects people of all age groups. Around 50 million people globally are epileptic, with 80% cases in developing countries due to lack of access to treatments determined by high cost and poor availability or it can be defined by the fraction of active epileptic patients who are not appropriately being treated. The availability of antiepileptic drugs and their adjuvant therapy in such countries is less than 50% and these are highly susceptible to drug interactions and severe adverse effects. As a result, the use of herbal medicine is increasingly becoming popular. To provide pharmacological information on the active constituents evaluated in the preclinical study to treat epilepsy with potential to be used as an alternative therapeutic option in future. It also provides affirmation for the development of novel antiepileptic drugs derived from medicinal plants. Relevant information on the antiepileptic potential of phytoconstituents in the preclinical study (in-vitro, in-vivo) is provided based on their effect on screening parameters. Besides, relevant information on pharmacology of phytoconstituents, the traditional use of their medicinal plants related to epilepsy and status of phytoconstituents in the clinical study were derived from online databases, including PubMed, Clinicaltrial. gov, The Plant List (TPL, www.theplantlist.org), Science Direct. Articles identified using preset searching syntax and inclusion criteria are presented. More than 70% of the phytoconstituents reviewed in this paper justified the traditional use of their medicinal plant related to epilepsy by primarily acting on the GABAergic system. Amongst the phytoconstituents, only cannabidiol and tetrahydrocannabinol have been explored for clinical application in epilepsy. The preclinical and clinical data of the phytoconstituents to treat epilepsy and its associated comorbidities provides evidence for the discovery and development of novel antiepileptic drugs from medicinal plants. In terms of efficacy and safety, further randomized and controlled clinical studies are required to understand the complete pharmacodynamic and pharmacokinetic picture of phytoconstituents. Also, specific botanical source evaluation is needed. [Display omitted]